E
CASI Pharmaceuticals, Inc. CASI
$0.96 -$0.03-2.80% NASDAQ
Recommendation
Prev Close
$0.96
Volume
64,013
Avg Vol (90D)
97,373
Market Cap
$19.73M
Dividend & Yield
--
52-Week Range
$0.75 - $3.09
P/E (TTM)
--
EPS (TTM)
-$2.12
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales
1/22/2026 - TipRanks Financial Blog
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 ...
1/15/2026 - GuruFocus
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
1/15/2026 - Zacks Investment Research
CASI Pharmaceuticals (CASI) Advances with Chinese Approval for CID-103 Trial
1/15/2026 - GuruFocus
Casi Pharmaceuticals announces NMPA approval of CTA for Phase 1/2 CID-103 study
1/15/2026 - TipRanks Financial Blog
Casi Pharmaceuticals announces NMPA approval of CTA for Phase 1/2 CID-103 study
1/15/2026 - The Fly
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
1/15/2026 - ACCESS Newswire
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in ...
1/12/2026 - GuruFocus
Casi Pharmaceuticals announces results from Phase 1 study of CID-103
1/12/2026 - The Fly
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
1/12/2026 - ACCESS Newswire
CASI Pharmaceuticals Inc. (NASDAQ:CASI) Short Interest Down 16.5% in December
1/2/2026 - Ticker Report
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
12/24/2025 - GuruFocus
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules
12/23/2025 - Seeking Alpha - Healthcare
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
12/23/2025 - ACCESS Newswire
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
12/11/2025 - GuruFocus
CASI Pharmaceuticals Secures $20 Million Investment Through Convertible Notes
12/11/2025 - GuruFocus
Casi Pharmaceuticals enters into $20M convertible note financing
12/11/2025 - The Fly
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
12/11/2025 - ACCESS Newswire
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th ...
12/8/2025 - GuruFocus
CASI Pharmaceuticals (CASI) Reports Promising Phase 1 Study Results for CID-103
12/8/2025 - GuruFocus
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results
12/8/2025 - The Fly
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
12/8/2025 - ACCESS Newswire
Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop
11/25/2025 - Simply Wall St
CASI Pharmaceuticals Announces Changes in Board Governance
11/19/2025 - GuruFocus
Casi Pharmaceuticals appoints James Huang as non-executive chairman
11/19/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$24.46M
Total Debt (Q)
$18.86M
Total Liabilities (Q)
$53.05M
Book Value Per Share (Q)
-$1.39
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
(est)
Price History
Loading...
Beta
1.09
7-Day Total Return
-5.88%
30-Day Total Return
13.81%
60-Day Total Return
-39.24%
90-Day Total Return
-52.24%
Year to Date Total Return
16.50%
1-Year Total Return
-63.91%
2-Year Total Return
-84.26%
3-Year Total Return
-52.94%
5-Year Total Return
-97.23%
52-week Low
Dec 24, 2025 - $0.75
52-week High
Aug 15, 2025 - $3.09
Valuation
Market Cap
$19.73M - Nano Cap
Enterprise Value
$33.90M
Price/Sales (TTM)
0.68
Price/Book (Q)
-0.69
Dividends and Shares
Shares Outstanding
16.05M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.casipharmaceuticals.com
Phone Number
86 10 6508 6063
Address
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road - Chaoyang District
Beijing, 100025
Country
China
Year Founded
1991
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed